A Randomized, Double-Blind, Placebo-Controlled Trial of Rifaximin, a Non-Absorbable Antibiotic, in the Treatment of Tropical Enteropathy.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Trial of Rifaximin, a Non-Absorbable Antibiotic, in the Treatment of Tropical Enteropathy.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Bacterial infections; Malabsorption syndromes
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 04 May 2009 Primary endpoint 'Clinical response' has not been met.
    • 04 May 2009 Results have been reported at the 2009 Annual Meeting of the Pediatric Academic Societies.
    • 11 Mar 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top